

**IN THE CLAIMS**

Please amend claim 1, and add new claims 7 and 8, as follows:

1. (Currently Amended) A method of identifying a candidate psychiatric patient for treatment with atypical antipsychotic or antidepressant medication that acts at a D2 dopamine receptor (DRD2) or influences D2 dopamine receptor density, the method comprising:

determining whether the patient's DRD2 genotype is Taq1A allele positive (A1+) or Taq1A allele negative (A1-); wherein:

the determining comprises genotyping a specimen obtained from the patient;

an A1+ genotype is indicative of a candidate for treatment with low dose DRD2 binding atypical antipsychotics and/or SSRIs; and

an A1- genotype is indicative of a candidate for treatment with high dose DRD2 dopamine receptor binding antipsychotics or alternative antidepressant.

2. (Original) The method of claim 1, wherein the psychiatric patient suffers from schizophrenia.

3. (Withdrawn) The method of claim 1, wherein the patient suffers from post-traumatic stress disorder (PTSD), depression, social anxiety or mixed anxiety and depressive states.

4. (Withdrawn) The method of claim 1, wherein the patient suffers from Parkinson's disease.

5. (Previously Presented) The method of claim 1, wherein the DRD2 binding antipsychotic is risperidone.

6. (Previously Presented) The method of claim 1, wherein the SSRI is paroxetine.

7. (New) The method of claim 1, wherein the genotyping comprises use of polymerase chain reaction (PCR).

8. (New) The method of claim 1, wherein the specimen comprises blood.